Systemic Therapies for Advanced Squamous Cell Anal Cancer

Systemic Therapies for Advanced Squamous Cell Anal Cancer Purpose of Review We aim to summarise the available evidence on systemic therapies for advanced anal cancer. Recent Findings There is no universal consensus on the management of this condition and the prognosis remains poor. Nevertheless, significant progress has been recently made including completion of the first, ever-conducted, randomised trial in the first-line setting, investigation of immunotherapy in the refractory setting and use of comprehensive genomic profiling for a better molecular characterisation of this disease and the identification of novel potential targets. Summary The combination of a platinum agent and a fluoropyrimidine is generally considered the standard first-line treatment. Other cytotoxic agents, especially docetaxel and paclitaxel, have shown activity in both the chemotherapy-naive and chemo- refractory setting and are currently being investigated in clinical trials. Finally, further to the promising results of early clinical trials, immunotherapy with checkpoint inhibitors (i.e. nivolumab and pembrolizumab) is likely to become a standard second-line treatment option. . . . . . . . Keywords Advanced anal cancer Systemic therapy Chemotherapy Cisplatin Carboplatin 5-Fluorouracil Capecitabine . . . . . . . . Paclitaxel Docetaxel Mitomycin Targeted therapy Cetuximab Panitumumab Immunotherapy Pembrolizumab . . . . Nivolumab LY2606368 HPV InterAACT Epitopes-HPV02 Introduction pecially genotypes http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Oncology Reports Springer Journals

Systemic Therapies for Advanced Squamous Cell Anal Cancer

Loading next page...
 
/lp/springer_journal/systemic-therapies-for-advanced-squamous-cell-anal-cancer-Waze2IWCvg
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology
ISSN
1523-3790
eISSN
1534-6269
D.O.I.
10.1007/s11912-018-0698-6
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review We aim to summarise the available evidence on systemic therapies for advanced anal cancer. Recent Findings There is no universal consensus on the management of this condition and the prognosis remains poor. Nevertheless, significant progress has been recently made including completion of the first, ever-conducted, randomised trial in the first-line setting, investigation of immunotherapy in the refractory setting and use of comprehensive genomic profiling for a better molecular characterisation of this disease and the identification of novel potential targets. Summary The combination of a platinum agent and a fluoropyrimidine is generally considered the standard first-line treatment. Other cytotoxic agents, especially docetaxel and paclitaxel, have shown activity in both the chemotherapy-naive and chemo- refractory setting and are currently being investigated in clinical trials. Finally, further to the promising results of early clinical trials, immunotherapy with checkpoint inhibitors (i.e. nivolumab and pembrolizumab) is likely to become a standard second-line treatment option. . . . . . . . Keywords Advanced anal cancer Systemic therapy Chemotherapy Cisplatin Carboplatin 5-Fluorouracil Capecitabine . . . . . . . . Paclitaxel Docetaxel Mitomycin Targeted therapy Cetuximab Panitumumab Immunotherapy Pembrolizumab . . . . Nivolumab LY2606368 HPV InterAACT Epitopes-HPV02 Introduction pecially genotypes

Journal

Current Oncology ReportsSpringer Journals

Published: May 4, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off